These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29176397)

  • 1. A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin.
    Inagaki C; Shimoi T; Okuma H; Kitano A; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Yoshida A; Fujiwara Y; Tamura K
    Anticancer Drugs; 2018 Jan; 29(1):97-101. PubMed ID: 29176397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma.
    Kawai A; Araki N; Naito Y; Ozaki T; Sugiura H; Yazawa Y; Morioka H; Matsumine A; Saito K; Asami S; Isu K
    Jpn J Clin Oncol; 2017 Feb; 47(2):137-144. PubMed ID: 28173193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma.
    Martorana F; Vigneri P; Manzella L; Tirrò E; Soto Parra HJ
    Future Oncol; 2020 Jan; 16(1s):9-13. PubMed ID: 31916463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
    J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
    McBride A; Butler SK
    Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma.
    Seetharam M; Kolla KR; Chawla SP
    Future Oncol; 2018 Jul; 14(16):1531-1545. PubMed ID: 29411654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eribulin mesylate.
    Jain S; Vahdat LT
    Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
    Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
    Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.
    Emambux S; Italiano A
    Expert Opin Pharmacother; 2017 Jun; 18(8):819-824. PubMed ID: 28468516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient.
    Miano ST; Francini E; Petrioli R; Francini G
    Future Oncol; 2020 Jan; 16(1s):33-38. PubMed ID: 31975628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eribulin as a Feasible and Safe Monotherapy in a Dialytic Pretreated Woman with Metastatic Breast Cancer: A Case Report.
    Nettuno R; Menditto C
    Oncology; 2018; 94 Suppl 1(Suppl 1):16-18. PubMed ID: 30036877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with eribulin in pretreated patients with advanced liposarcoma: a case series.
    Paioli A; Setola E; Palmerini E; Cesari M; Longhi A
    Future Oncol; 2020 Jan; 16(1s):25-32. PubMed ID: 31858818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
    Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
    J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of cutaneous angiosarcoma successfully treated with eribulin.
    Iwamoto K; Fujisawa Y; Ishitsuka Y; Maruyama H; Nakamura Y; Okiyama N; Watanabe R; Fujimoto M
    Eur J Dermatol; 2018 Jun; 28(3):410-412. PubMed ID: 29619993
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.
    Wiemer EAC; Wozniak A; Burger H; Smid M; Floris G; Nzokirantevye A; Sciot R; Sleijfer S; Schöffski P
    Eur J Cancer; 2017 Apr; 75():33-40. PubMed ID: 28214655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital.
    Poletti P; Ghilardi V; Livraghi L; Milesi L; Rota Caremoli E; Tondini C
    Future Oncol; 2014 Feb; 10(2):233-9. PubMed ID: 24490609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
    Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
    J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical experiences with eribulin in patients with metastatic breast cancer.
    Tesch H; Schneeweiss A
    Anticancer Drugs; 2016 Feb; 27(2):112-7. PubMed ID: 26488444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary cardiac rhabdomyosarcoma successfully treated with eribulin: a case report.
    Ota S; Shimonaga T; Yuki S; Kuraoka K; Ogawa T; Hirata T
    Anticancer Drugs; 2020 Mar; 31(3):304-309. PubMed ID: 31725047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of eribulin mesylate for the treatment of metastatic breast cancer].
    Matsuzaki H; Tohnosu N; Yoshiwara C; Maruyama T; Tanaka H; Natsume T; Miyazaki A; Sato Y; Ohta T; Yamamoto Y; Aikawa M; Ohtsuka R; Yanagihara A; Iwata K; Shiratori T; Miyazawa Y
    Gan To Kagaku Ryoho; 2014 Apr; 41(4):455-9. PubMed ID: 24743360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.